Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT)

Circulation

Volumn 98, Issue 23, 1998, Pages 2574-2579

  Deedwania, Prakash C ^a,b,f   Singh, Bramah N ^c   Ellenbogen, Kenneth ^g   Fisher, Susan ^e   Fletcher, Ross ^d   Singh, Steven N ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Veterans Affairs Cooperative Studies Program Coordinating Center   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NONE

Author keywords

Drugs; Fibrillation, atrial; Heart failure; Survival

Indexed keywords

AMIODARONE;

ADULT; AGED; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; DRUG EFFECT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE POTENTIAL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINUS RHYTHM;

EID: 0032497913     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.23.2574     Document Type: Article

References (32)

1. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort study: the Framingham Heart Study. JAMA. 1994;271:840-844.
2. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med. 1995;155:469-473.
3. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-up Study. Am J Med. 1995;98:476-484.
4. Onundarson PT, Thorgeirsson G, Jonmundsson E, Sigfusson N, Hardarson T. Chronic atrial fibrillation: epidemiologic features and 14 years follow-up: a case-control study. Eur Mean J. 1987;3:521-527.
5. The AFFIRM Investigators. Atrial fibrillation following investigation of rhythm management (AFFIRM) study design. Am J Cardiol. 1997;79: 1198-1202.
6. Nattel S. Newer developments in the management of atrial fibrillation. Am Heart J. 1995;130:1094-1106.
7. Sopher SM, Camm AJ. Atrial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol. 1996;77:24A-37A.
8. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation. 1991;84:40-48.
9. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336: 525-533.
10. Singh BN. Controlling cardiac arrhythmias: an overview with a historical perspective. Am J Cardiol. 1997;80:4G-15G.
11. Singh BN. Expanding indications for the use of class III antiarrhythmic agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol. 1995;6;887-900.
12. Hohnloser S, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: a review with special reference to torsades de pointes tachycardia. Ann Intern Med. 1994;121:529-538.
13. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 1995;333:77-82.
14. Middlekauff HR, Wiener I, Saxon LA, Stevenson WG. Low-dose amiodarone for atrial fibrillation: time for a prospective study? Ann Intern Med. 1992;116:1017-1020.
15. Graboys TB, Podrid PJ, Lown B. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J. 1983;106:870-876.
16. Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, Brady PM, Kay HR. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol. 1985;6:1402-1407.
17. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol. 1995;76:47-50.
18. Gosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA. 1992;267:3289-3293.
19. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol. 1986;57:124-127.
20. Brodsky MA, Allen BJ, Walker CJ II, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol. 1987;60: 572-575.
21. Blevins RD, Kerin NZ, Benaderet D, Frumin H, Faitel K, Jarandilla R, Rubinfire M. Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med. 1987;147:1401-1404.
22. Skoularigis J, Röthlisberger C, Skudicky D, Essop MR, Wisenbaugh T, Sareli P. Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. Am J Cardiol. 1993;72:423-427.
23. Zarembski DG, Nolan PE, Slack MK, Caruso AC. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med. 1995;155:1885-1891.
24. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation. 1990; 82:1106-1116.
25. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 1990;82:1932-1939.
26. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. Am J Cardiol. 1992;20: 527-532.
27. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol. 1970;39: 657-667.
28. Ikeda N, Nademanee K, Kannan R, Singh BN. Electrophysiologic effects of amiodarone: experimental and clinical observations relative to serum and tissue drug concentrations. Am Heart J. 1984;108: 890-898.
29. Olsson SB, Brorson L, Varnauskas E. Class 3 antiarrhythmic actions in man: observations from monophasic action potential recordings and amiodarone treatment. Br Heart J. 1973;35:1255-1259.
30. Kodama I, Kamiya K, Toyoma K. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35:13-29.
31. Hamer AF, Ankles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J Am Coll Cordiol. 1989;14:1768-1774.
32. Daoud EG, Strickberger A, Man C, Goyal R, Deeb GM, Boiling SF, Bita C, Meissner MD, Morady F. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med. 1997;337: 1785-1791.